Home>Topics>Authors>Damien Conover

Damien Conover

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Friday Five: China's Tricky Gambit for Growth

    Video Reports

    Thu, 11 Dec 2014

    acquiring Cubist. What's our take on the deal? Glaser: Merck is going to spend $9.5 billion for Cubist, and Damien Conover , our health-care analyst, thinks this is about expanding Merck's presence into the hospital acute-care segment

    Damien Conover found at 3:26

    deal? Glaser: Merck is going to spend $9.5 billion for Cubist, and Damien Conover , our health-care analyst, thinks this is about expanding Merck's presence into the hospital acute-care segment, and he thinks that's something that will
  2. A Shift in Health-Care M&A Activity

    Headlines

    Sat, 23 Aug 2014

    rest of 2014 might hold for M&A activity in health care, I recently talked with Morningstar health-care analysts Damien Conover , David Krempa, and Michael Waterhouse on May 31. Our discussion has been edited for clarity and length. Question

  3. Health Care a Leader in Moat Stocks

    Video Reports

    Tue, 22 Jul 2014

    great competitive advantages. I'm here today with Damien Conover , our director of health-care research, to look ..... health-care space. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser: You wrote

    Damien Conover found at 0:11

    delves into finding companies with great competitive advantages. I'm here today with Damien Conover , our director of health-care research, to look at moats in the health-care space. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser: You wrote in the book that health-care companies have a higher preponderance of moats than a
  4. The Friday Five

    Video Reports

    Fri, 18 Jul 2014

    the coming years from other companies, so that growth will moderate. But they have a pretty strong pipeline, and Damien Conover , our [TICKER:JNJ] Johnson & Johnson analyst, really sees that their patent losses are pretty manageable

    Damien Conover found at 5:05

    that growth will moderate. But they have a pretty strong pipeline, and Damien Conover , our [TICKER:JNJ] Johnson & Johnson analyst, really sees that their patent losses are pretty manageable. [Those patent losses] tend to be in products
  5. J&J's Strong 2Q Led by Pharmaceuticals

    Headlines

    Tue, 15 Jul 2014

    Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover .

  6. The Friday Five

    Video Reports

    Thu, 8 May 2014

    includes things like Claritin, Coppertone, and Dr. Scholl's foot insoles--and sending them over to Bayer. Damien Conover , our health-care analyst, thinks this is a good deal for both sides. Merck is getting a good price for these

    Damien Conover found at 2:54

    Claritin, Coppertone, and Dr. Scholl's foot insoles--and sending them over to Bayer. Damien Conover , our health-care analyst, thinks this is a good deal for both sides. Merck is getting a good price for these businesses right
  7. The Friday Five

    Video Reports

    Thu, 1 May 2014

    AstraZeneca possibly having a deal. What's our take on this? Glaser: This deal likely makes a lot more sense. Damien Conover , our health-care analyst, sees [TICKER:AZN] AstraZeneca as having somewhat of the bloated cost structure

    Damien Conover found at 2:35

    take on this? Glaser: This deal likely makes a lot more sense. Damien Conover , our health-care analyst, sees [TICKER:AZN] AstraZeneca as having somewhat of the bloated cost structure. Pfizer would be able to come in and get
  8. Pfizer-Astra Deal Will Get Done

    Video Reports

    Mon, 28 Apr 2014

    Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover .

  9. Johnson & Johnson's Pharma Group Leading the Way

    Video Reports

    Tue, 15 Apr 2014

    The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover .

  10. The Sector Is Fairly Valued, but These Stocks Are Not

    Video Reports

    Thu, 10 Apr 2014

    investments, the market, economic indicators, and more. Join us every day for fresh insights from our analyst team. Damien Conover : Today we're talking about health care, and when we think about health care, there are a lot of different industries

    Damien Conover found at 0:03

    more. Join us every day for fresh insights from our analyst team. Damien Conover : Today we're talking about health care, and when we think about health care, there are a lot of different industries within health
« Prev123Next »
Content Partners